Form 4: Arteris CEO Sells $1.9M in Stock
Insider Transaction Report
Arteris Inc.'s President and CEO, Charles Janac, sold 144,245 shares of common stock for approximately $1.9 million under a pre-arranged 10b5-1 trading plan.
Summary
- Charles K. Janac, President and CEO, Director, and 10% owner of Arteris, Inc. (AIP), reported sales of common stock.
- A total of 144,245 shares were sold on August 5, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on March 5, 2025.
- 94,245 shares were sold at a weighted average price of $13.4874, with prices ranging from $12.57 to $14.20.
- An additional 50,000 shares were sold at a weighted average price of $13.1199, with prices ranging from $12.35 to $14.20.
- The total proceeds from these sales amount to approximately $1,927,194.
- Following these transactions, Janac directly owns 189,785 shares.
- Indirect ownership includes 9,839,071 shares via Bayview Legacy, LLC, and 56,252 shares via Charles and Lydia Janac Trust.
Sentiment
Score: 5
Explanation: The transactions were conducted under a pre-arranged 10b5-1 trading plan, which typically indicates a scheduled liquidity event rather than a reaction to new company developments, thus having a neutral immediate sentiment.
Future Outlook
This filing is a report of past insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
Insider stock sales, particularly when conducted under a pre-arranged 10b5-1 trading plan, are a common practice for executives to manage personal liquidity and diversification. Such plans are designed to allow insiders to sell shares without being accused of trading on material non-public information, as the sales schedule is set in advance.
Stakeholder Impact
- Shareholders may perceive insider selling as a negative signal, but the execution under a 10b5-1 plan mitigates concerns about the timing being based on undisclosed material information.
Key Dates
| Date | Description |
|---|---|
| March 5, 2025 | Rule 10b5-1 trading plan adopted by the Reporting Person. |
| August 5, 2025 | Date of common stock sales by the Reporting Person. |
| August 7, 2025 | Date the Form 4 was filed. |
Recommendation
holdThe insider sales were conducted under a pre-arranged 10b5-1 trading plan, which suggests a planned liquidity event rather than a reflection of new negative company information. Therefore, this filing alone does not warrant a change in investment recommendation.
Keywords
Arteris, AIP, insider trading, stock sale, CEO, Form 4, 10b5-1 plan, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.